-
Mashup Score: 1Dr. Soon-Shiong discusses the FDA approval of N-803 in NMIBC - 15 hour(s) ago
“All this is very detailed immunology, I get that, but it sets the stage for what I consider the next evolution of immunotherapy,” says Patrick Soon-Shiong, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 8
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3Dr. Narayan on next steps with nadofaragene firadenovec in NMIBC - 1 month(s) ago
“The hope is that we can collaborate with folks who might be interested in trying nadofaragene plus something else, something that compliments the mechanism of action, so that we can build upon what we have now,” says Vikram M. Narayan, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 4Urine-based assay demonstrates predictive efficacy in MIBC - 1 month(s) ago
The AssureMDx test demonstrated an area under the curve of 0.80 in detecting urinary tract recurrences in MIBC.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 7
“Real-world data has a real place in demonstrating some of these findings and allowing us to ask better questions,” says Bogdana Schmidt, MD, MPH.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
Dr. Patrick Soon-Shiong discusses the recent FDA approval of N-803 for BCG-unresponsive NMIBC. @DrPatSoonShiong #blcsm #urology https://t.co/yH9nUQOzUn